All In Biotech

Drug Trial Radar · NCT02730377

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting

Last checked: Nov 19, 2026Latest source record: Jul 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,991 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,991

Actual

Start

Mar 28, 2016

Primary completion

Aug 5, 2019

Study completion Aug 12, 2019

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • liraglutideDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • alpha-glucosidase inhibitorsDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • DPP-4 inhibitorsDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • meglitinidesDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • SGLT-2 inhibitorsDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • sulphonylureaDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • thiazolidinedionesDrug

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Inadequate Glycaemic ControlTime frame: Weeks 26-104

Locations

232 sites in 10 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Haleyville, Alabama

  • Novo Nordisk Investigational Site

    Tuscumbia, Alabama

  • Novo Nordisk Investigational Site

    Fountain Hills, Arizona

  • Novo Nordisk Investigational Site

    Phoenix, Arizona

  • Novo Nordisk Investigational Site

    Phoenix, Arizona

  • Novo Nordisk Investigational Site

    Phoenix, Arizona

  • Novo Nordisk Investigational Site

    Tempe, Arizona

  • Novo Nordisk Investigational Site

    Tucson, Arizona

  • Novo Nordisk Investigational Site

    Harrisburg, Arkansas

  • Novo Nordisk Investigational Site

    Little Rock, Arkansas

  • Novo Nordisk Investigational Site

    North Little Rock, Arkansas

  • Novo Nordisk Investigational Site

    Searcy, Arkansas

  • Novo Nordisk Investigational Site

    Alhambra, California

  • Novo Nordisk Investigational Site

    Buena Park, California

  • Novo Nordisk Investigational Site

    Carlsbad, California

  • Novo Nordisk Investigational Site

    Coronado, California

  • Novo Nordisk Investigational Site

    Costa Mesa, California

  • Novo Nordisk Investigational Site

    Elk Grove, California

  • Novo Nordisk Investigational Site

    Encinitas, California

  • Novo Nordisk Investigational Site

    Huntington Beach, California

  • Novo Nordisk Investigational Site

    La Mirada, California

  • Novo Nordisk Investigational Site

    Lancaster, California

  • Novo Nordisk Investigational Site

    Lomita, California

  • Novo Nordisk Investigational Site

    Montclair, California

  • Novo Nordisk Investigational Site

    Northridge, California

  • Novo Nordisk Investigational Site

    Oxnard, California

  • Novo Nordisk Investigational Site

    Rancho Cucamonga, California

  • Novo Nordisk Investigational Site

    Riverside, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Ramon, California

  • Novo Nordisk Investigational Site

    Tustin, California

  • Novo Nordisk Investigational Site

    Westminster, California

  • Novo Nordisk Investigational Site

    Centennial, Colorado

  • Novo Nordisk Investigational Site

    Centennial, Colorado

  • Novo Nordisk Investigational Site

    Colorado Springs, Colorado

  • Novo Nordisk Investigational Site

    Golden, Colorado

  • Novo Nordisk Investigational Site

    Monument, Colorado

  • Novo Nordisk Investigational Site

    Chiefland, Florida

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.